[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100181068":3},{"organization":4,"armGroups":7,"interventions":41,"overallOfficials":59,"centralContacts":11,"locations":63,"responsibleParty":75,"collaborators":11,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":11,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":85,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":11,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":102,"whyStopped":11,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Janssen Research & Development, LLC","INDUSTRY",[8,15,19,23,26,29,32,35,38],{"label":9,"type":10,"description":11,"interventionNames":12},"Japanese Group 1: JNJ-39439335\u002Fplacebo (Part 1)","EXPERIMENTAL",null,[13,14],"Drug: JNJ-39439335 10 mg","Drug: Placebo",{"label":16,"type":10,"description":11,"interventionNames":17},"Japanese Group 2: JNJ-39439335\u002Fplacebo (Part 1)",[18,14],"Drug: JNJ-39439335 25 mg",{"label":20,"type":10,"description":11,"interventionNames":21},"Japanese Group 3: JNJ-39439335\u002Fplacebo (Part 1)",[22,14],"Drug: JNJ-39439335 50 mg",{"label":24,"type":10,"description":11,"interventionNames":25},"Caucasian Group 1: JNJ-39439335\u002Fplacebo (Part 1)",[13,14],{"label":27,"type":10,"description":11,"interventionNames":28},"Caucasian Group 2: JNJ-39439335\u002Fplacebo (Part 1)",[18,14],{"label":30,"type":10,"description":11,"interventionNames":31},"Caucasian Group 3: JNJ-39439335\u002Fplacebo (Part 1)",[22,14],{"label":33,"type":10,"description":11,"interventionNames":34},"Japanese Group 1: JNJ-39439335\u002Fplacebo (Part 2)",[13,14],{"label":36,"type":10,"description":11,"interventionNames":37},"Japanese Group 2: JNJ-39439335\u002Fplacebo (Part 2)",[18,14],{"label":39,"type":10,"description":11,"interventionNames":40},"Japanese Group 3: JNJ-39439335\u002Fplacebo (Part 2)",[22,14],[42,47,51,55],{"type":43,"name":44,"description":45,"armGroupLabels":46,"otherNames":11},"DRUG","JNJ-39439335 10 mg","Multiple (once daily for 21 days) oral doses of JNJ-39439335 10 mg.",[24,9,33],{"type":43,"name":48,"description":49,"armGroupLabels":50,"otherNames":11},"JNJ-39439335 25 mg","Multiple (once daily for 21 days) oral doses of JNJ-39439335 25 mg.",[27,16,36],{"type":43,"name":52,"description":53,"armGroupLabels":54,"otherNames":11},"JNJ-39439335 50 mg","Multiple (once daily for 21 days) oral doses of JNJ-39439335 50 mg.",[30,20,39],{"type":43,"name":56,"description":57,"armGroupLabels":58,"otherNames":11},"Placebo","Multiple (once daily for 21 days) oral doses of matching placebo.",[24,27,30,9,33,16,36,20,39],[60],{"name":61,"affiliation":5,"role":62},"Janssen Research & Development, LLC Clinical Trial","STUDY_DIRECTOR",[64],{"facility":11,"status":11,"city":65,"state":66,"zip":11,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":11},"Cypress","California","United States","US",{"type":70,"coordinates":71},"Point",[72,73],-118.03729,33.81696,{"lat":73,"lon":72},{"type":76,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100181068","phase-1-a-study-to-investigate-the-safety-tolerability-and-pharmacokinetics-of-jnj-39439335-in-healthy-japanese-and-caucasian-adult-male-participants-100181068",false,"NCT01631487","A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants","A Double-Blind, Randomized, Placebo-Controlled, Sequential Group, Single Ascending and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Subjects","Inclusion Criteria:\n\n* Japanese or Caucasian participants\n* Nonsmoker\n* Body Mass Index (BMI) of 18 to 30 kg\u002Fm2, inclusive, and body weight not less than 50 kg\n* Healthy on the basis of a physical examination, vital signs, hematology, coagulation, serum chemistry (including liver function tests) and urinalysis\n* Willing to adhere to the prohibitions and restrictions specified by the study protocol\n\nExclusion Criteria:\n\n* Oral temperatures \\> 37.5 Celsius degrees\n* Participants who have occupations or hobbies in which they are routinely exposed to situations in which they could sustain thermal burns\n* Abnormal electrocardiogram (ECG) results\n* Clinically significant abnormal values for hematology, clinical chemistry or urinalysis\n* History of or current clinically significant medical illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results",true,"MALE","20 Years","55 Years",{"count":89,"type":90},86,"ACTUAL","INTERVENTIONAL",[93],"PHASE1","The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics of JNJ-39439335 in healthy Japanese and Caucasian adult male participants in Part 1, and in healthy Japanese adult male participants in Part 2.",[96],"Healthy",[96,98,99,100,101],"JNJ-39439335","Japanese","Caucasian","Male","COMPLETED","2013-06-24",{"date":105,"type":106},"2013-06-25","ESTIMATED",{"date":108,"type":11},"2012-07",{"date":110,"type":90},"2013-03",{"name":5,"class":6},1]